Stirling-based pharma group Symbiosis appoints chief operating officer
Stirling-headquartered Symbiosis Pharmaceutical Services has appointed John Mccormick as chief operating officer and hailed its recent business growth.
The firm, which specialis-es in the sterile manufacture of vaccines, pharmaceuticals and biopharmaceuticals, said
Mccormick would become an executive member of its board of directors.
Previously operations development director at the company, Mccormick has 15 years of experience in the pharmaceutical and biotechnology industry in various roles.
Chief executive Colin Mackay said: “Our expertise in small-to-medium scale clinical trial and commercial sterile manufacturing continues to resonate successfully with our target client market, as demonstrated by repeated annual business growth of around 25 per cent.
“Our recent successes in manufacturing Covid -19 candidate vaccine further underlines the competitive strengths of Symbiosis.
“John’ s promotion and appointment to the board of directors is part of a long-term strategy to support the continued organic growth of our core sterile manufacturing services in the US and Europe and a reflection of his achievement to date, our success in the market, and my confidence in his abilities.”
Mccormick added: “In the last 12 months Symbiosis has grown its sterile bio logic s manufacturing capabilities significantly and the company has invested over £1.5 million in its expansion, doubling its physical footprint and creating fresh operational challenges.
“These are exciting times for Symbiosis and I look forward to playing a key role in the next chapter of the company’s rapid development.”
The firm also has an office in Cambridge, Massachusetts.